InMed Pharmaceuticals Inc.

InMed Pharmaceuticals maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 3.11, indicating strong short-term liquidity coverage. The company holds $5.16 million in cash and equivalents against total assets of $9.13 million and total liabilities of $2.24 million. However, the firm generated negative operating cash flow of -$5.68 million in Q3 2026, reflecting significant cash burn. The market capitalization stands at $6.62 million, trading at a price-to-book ratio of 1.23. The substantial difference between basic shares outstanding (3.31 million) and diluted shares outstanding (3.99 million) signals high potential dilution from options, warrants, or convertible instruments.

Profitability metrics are deeply negative, with a return on equity of -1.18 and a return on assets of -0.89, consistent with a pre-revenue or early-stage clinical company burning cash for R&D. The net income for Q3 2026 was -$6.72 million. The company lacks meaningful revenue generation, as evidenced by an EV/Revenue ratio of 0.29, which implies negligible top-line sales relative to its enterprise value. This profile is typical for small-cap biotechs that have not yet achieved commercial scale, relying entirely on capital markets for survival rather than operational cash flows.

The company’s business model centers on proprietary manufacturing approaches for cannabinoids, including the IntegraSyn technology, and the development of pharmaceutical drug candidates. A key operational risk involves the winding down of the BayMedica commercial business segment due to recent U.S. legislation impacting its inventory of rare, non-intoxicating cannabinoids. The firm outsources the majority of its R&D activities to scientific collaborators, academic institutions, and contract development and manufacturing organizations (CDMOs). There is no disclosed geographic revenue mix, suggesting the company is in a pre-commercial phase with no significant regional sales concentration.

Growth trajectory is characterized by persistent operating losses and cash consumption. For the six months ended December 31, 2025, the company reported a net loss of $3.76 million, compared to $4.25 million in the prior year period, showing a slight improvement in loss magnitude but continued negative performance. Cash used in operating activities was $3.98 million for the six months ended December 31, 2025, down from $4.33 million in the prior year. The company’s cash position declined from $11.08 million at the beginning of the period to $6.95 million at the end of the six-month period in 2025. This trend underscores the urgent need for additional financing to sustain operations.

Risk assessment highlights high liquidity risk due to the going-concern qualification and high dilution risk from the wide gap between basic and diluted share counts. Key flags include filings referencing substantial doubt about the company’s ability to continue as a going concern and source documents mentioning dilution or offering risk. The company faces significant regulatory and operational risks, including FDA acceptance of product candidates, patent prosecution, and the success of strategic partnerships. Additionally, the company cites geopolitical risks, including the Russo-Ukrainian war and Middle East hostilities, as potential factors affecting its operations and supply chain.

Recent events include an extraordinary price move on July 22, 2026, where the stock surged 20.67% to $1.81 on volume 1,175 times the 20-day average, indicating speculative interest or a specific catalyst not detailed in the provided data. The company has disclosed partial coverage in Companyfacts, with recent filings backfilling accounts receivable, inventory, and accounts payable. Management continues to emphasize the need to stem operating losses and secure additional financing to fund operations and strategic opportunities.

InMed maintains a strong liquidity position with a current ratio of 6.99, significantly above the pharmaceutical cohort median.

The company exhibits low leverage with a debt-to-equity ratio of 0.16, ranking in the top quartile of its peer group.

Revenue demonstrated a 5.4% compound annual growth rate from fiscal 2023 to fiscal 2025, indicating top-line expansion.

Gross profit increased to $1.7 million in fiscal 2025, suggesting some improvement in core operational efficiency despite net losses.

InMed faces high liquidity and dilution risks, posing significant threats to shareholder value and operational continuity.

The company reported a net loss of $8.2 million in fiscal 2025, reflecting persistent inability to achieve profitability.

Free cash flow remained negative at -$7.0 million in fiscal 2024, highlighting ongoing cash burn and funding dependencies.

Revenue $1.9M; Net margin -193.5%.

• ▍Revenue $1.9M
• ▍Net margin -193.5%

Revenue $1.1M; Net margin -154.2%.

• ▍Revenue $1.1M
• ▍Net margin -154.2%

Revenue $4.9M; Net margin -165.1%.

• ▍Revenue $4.9M
• ▍Net margin -165.1%

Revenue $4.6M; Net margin -166.9%.

• ▍Revenue $4.6M
• ▍Net margin -166.9%

Revenue $4.6M; Net margin -166.9%.

• ▍Revenue $4.6M
• ▍Net margin -166.9%

Revenue $4.1M; Operating income -$7.9M.

• ▍Revenue $4.1M
• ▍Operating income -$7.9M
• ▍Net margin -192.2%

Revenue $4.1M; Net margin -192.2%.

• ▍Revenue $4.1M
• ▍Net margin -192.2%